The highest risk cohorts are as defined in the Interim Clinical Policy developed by the Rapid C-19 policy expert group. A list of the cohort categories is attached to this letter for ease of reference.
Access to these treatments will be directly through Trust-provided, Outpatient COVID-19 Treatment Services (OCTs).
Patients who do not have a positive COVID diagnosis but who make contact regarding access to treatment.
Advice should be that the treatments are available only to those patients in the identified cohorts and who have a positive COVID diagnosis.
All Trusts have indicated that patients will be contacted irrespective of whether the initial clinical triage suggests that treatment is or is not appropriate. There may be occasions when there is a delay in making contact e.g. at weekends or if the Trust clinician is unable to get through on the phone. It is anticipated that the occasions when contact is not made by the Trust will be rare.
If you receive contact from a patient on this basis you should provide reassurance that the Trust will be in contact but that this might take a day or two – particularly over a weekend. If you have a particular concern about any patient in this category, Trusts can be contacted by e-mail or phone via the details set out in the Table 1 below.
The process to centrally identify patients potentially eligible for treatment will be refined as processes develop. The database of patients will be updated regularly with a view to ensuring that as many patients as possible are included and identified for matching against the daily COVID positive test results.
Patients must meet all of the eligibility criteria and none of the
exclusion criteria. Pre-hospitalised patients are eligible to be
– SARS-CoV-2 infection is confirmed by polymerase chain
reaction (PCR) testing within the last 5 days; AND
– Onset of symptoms of COVID-19 within the last 5 days; AND
– A member of a ‘highest’ risk group (as defined in Appendix 1
of NHS Clinical Commissioning Policy).
Patients are not eligible for nMAB treatment if they meet any of the
– Require hospitalisation for COVID-19; OR
– Require NEW supplemental oxygen specifically for the
management of Covid19; OR
– Children weighing less than 40kg; OR
– Children aged under 12 years
|Trust||OCT Email Address||Phone Number|
|Belfast||[email protected]||02896 155034|
|North||[email protected]||02894 424000 ext 331361|
|South East||[email protected]||02891 475116|
|Southern||[email protected]||02837 560601|
|West||[email protected]||02871 610816|
Appendix 1: Patient cohorts considered at highest risk from COVID-19 and to be prioritised for treatment with nMABs
The following patient cohorts were determined by an independent advisory group commissioned by the Department of Health and Social Care (DHSC)7.
|Down’s syndrome||All patients with Down’s syndrome|
|Patients with a solid cancer|
|Patients with a haematological diseases and stem cell transplant recipients|
|Patients with renal disease|
|Patients with liver disease|
|Patients with immune-mediated inflammatory disorders (IMID)|
|Primary immune deficiencies|
|Solid organ transplant recipients||All recipients of solid organ transplants not otherwise specified above|
|Rare neurological conditions|
7 For paediatric/adolescent patients (aged 12-17 years inclusive), paediatric multi-disciplinary team (MDT) assessment should be used to determine clinical capacity to benefit from the treatment